It was anything but a quiet August for healthcare M&A. Chris Wilson, a partner at Goodwin’s private equity group and co-chair of the healthcare practice, described a “tale of two cities.” Read The Deal article here.
Related Content
- AlertMarch 24, 2026
FTC Launches Healthcare Task Force, Signaling Heightened Antitrust and Consumer Protection Enforcement
- AlertMarch 23, 2026
Ninth Circuit Enables 340B False Claims Act Enforcement
- AlertMarch 5, 2026
Fifth Circuit Adopts Narrow Interpretation of Two Critical DEA Regulations
- InsightFebruary 17, 2026
Antitrust & Competition Healthcare Year in Review 2025
- AlertFebruary 13, 2026
Express Scripts Settles PBM FTC Action and Must Make Fundamental Changes to PBM Model
- AlertFebruary 11, 2026
OIG’s Latest Guidance Targets Medicare Advantage Fraud
- Health HeadlinesJanuary 30, 2026
Health Headlines: January 2026
- AlertJanuary 29, 2026
Historic False Claims Act Enforcement Illustrates Trump Administration’s Focus on Healthcare Fraud
- WebinarApril 22, 2026
Digital Health Startup Survival Guide: FDA, HIPAA, AI & Beyond
- In the PressApril 1, 2026
Factors Driving Change For Medtechs And Biotechs – A Legal View (In Vivo)
- EventsMarch 31, 2026
2026 ACG NY 18th Annual Healthcare Conference
- Press ReleaseMarch 31, 2026
Goodwin Advises WHOOP on $575 Million Series G Financing to Accelerate Global Health Platform Expansion
- In the PressMarch 31, 2026
As FCA Meets 340B, Geyser Of Qui Tam Suits May Erupt (Law360)
- Awards and Rankings26 March 2026
Legal 500 EMEA 2026 Recognizes Goodwin for Excellence in France, Germany, and Luxembourg
- Press ReleaseMarch 16, 2026
Goodwin Advised Templewater on the Acquisition of The Women’s Clinic Group
- Press ReleaseFebruary 17, 2026
Goodwin Guides Gannet BioChem on Acquisition of Laysan Bio